Pharmacist-Led Strategies for Adverse Event Management in mCRC

March 25, 2025

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Melody Chang, RPh, MBA, BCOP

Opinion

Video

Experts discuss how pharmacists contribute to managing adverse events and toxicity for patients undergoing metastatic colorectal cancer (mCRC) treatment. They explore the factors influencing patient adherence to third-line therapies and ways pharmacists can improve patient education to enhance adherence to treatment regimens.

EP: 1.Treatment Options in mCRC: A Clinical Overview

EP: 2.Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP: 3.Quality of Life and Patient Outcomes in mCRC Treatment

EP: 4.Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP: 5.The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP: 6.Evolution of Oncology Pharmacy Practice in mCRC

Now Viewing

EP: 7.Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP: 8.Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP: 9.Best Practices for Overcoming mCRC Prior Authorization Barriers

EP: 10.Building Better Collaboration: Reducing Care Delays in Managing mCRC

Video content above is prompted by the following:

In what ways do pharmacists contribute to managing adverse events and toxicity for patients undergoing mCRC treatment?
What factors influence patient adherence to third-line therapies for mCRC, and how can pharmacists improve patient education to address these challenges and ensure better adherence to treatment regimens?